Vivere Continues Strong Growth Trajectory with Launching New Fertility Practice and IVF Laboratory in Tennessee
Nashville location, set to open in early 2016, will provide Tennessee patients access to some of the highest success rates in the country through Vivere’s proven clinical outcomes
NASHVILLE, Tenn. (October 16, 2015) – Vivere, a fertility management and equity partner, will soon begin construction on Tennessee Fertility Institute (TFI), a fertility practice and in vitro fertilization (IVF) laboratory to be located just south of Nashville in the Franklin area.
Slated to open in early 2016, TFI will offer comprehensive reproductive healthcare services, including in vitro fertilization (IVF), elective egg freezing, access to donors and surrogates and fertility preservation services for oncology patients. The 6,000-square-foot-Institute will feature an on-site fertility clinic, as well as innovative technology with a state-of-the-art IVF laboratory.
“As a Nashville-based company, we are delighted to establish Tennessee Fertility Institute and bring our life-changing fertility services to the Nashville area,” said Debbie James, Vivere president and CEO. “The Nashville metro area is an important, strategic location for us, and we look forward to bringing advanced fertility treatment options to patients in this rapidly-growing area.”
Medical Director for TFI will be Donna Session, M.D., Vanderbilt University Medical Center’s Division Director for Reproductive Endocrinology and Infertility.
Prior to joining Vanderbilt, Session served as Director of the Division of Reproductive Endocrinology and Infertility at Emory University School of Medicine. She is a graduate of Allegheny College and earned her medical degree from Eastern Virginia Medical School in 1986. Session completed her residency at Winthrop University Hospital, followed by a fellowship at Columbia University, where she was a Sloane Scholar.
“Working with Vivere allows us to provide patients with world-class fertility care in a facility that is both technologically advanced and highly patient-focused,” Session said. “We will be able to produce superior clinical outcomes and exceptional patient experiences for patients throughout Tennessee.”
The new Nashville location further enhances Vivere’s growth trajectory. The company has been consistently honored for its growth, including recognition as one of the 20 Fastest Growing Private Companies by the Nashville Business Journal in 2015. In just the last three years, Vivere has increased overall revenue by 91% through organic growth by developing partnerships with forward-thinking physicians, as well as building and managing de novo practices, IVF laboratories and ambulatory surgery centers. Vivere is leveraging overall growth in the fertility industry, which, according to a 2014 Allied Market Research report, is projected to reach $21.6 billion in 2020.